Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    Article Recommendations from Our Deputy and Senior Editors
    Cancer Immunol Res December 1 2016 4 (12) 995-995;

Meeting Report

  • Meeting Report
    Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference
    Arthur N. Brodsky and Vanessa M. Hubbard-Lucey
    Cancer Immunol Res December 1 2016 4 (12) 996-1000; DOI:10.1158/2326-6066.CIR-16-0276

Cancer Immunology at the Crossroads

  • Cancer Immunology at the Crossroads
    Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul
    Greg M. Delgoffe
    Cancer Immunol Res December 1 2016 4 (12) 1001-1006; DOI:10.1158/2326-6066.CIR-16-0244

Research Articles

  • Research Articles
    Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach
    Tanner M. Johanns, Jeffrey P. Ward, Christopher A. Miller, Courtney Wilson, Dale K. Kobayashi, Diane Bender, Yujie Fu, Anton Alexandrov, Elaine R. Mardis, Maxim N. Artyomov, Robert D. Schreiber and Gavin P. Dunn
    Cancer Immunol Res December 1 2016 4 (12) 1007-1015; DOI:10.1158/2326-6066.CIR-16-0156

    Immunogenomics were used to identify tumor-specific neoantigens in two well characterized models of glioblastoma. Endogenous immune responses harbored neoantigen-specific T cells within the brain and lymph nodes, providing a tractable system for additional preclinical immunotherapeutic studies in these systems.

  • Research Articles
    Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
    Lauryn E. Klevorn, Melissa M. Berrien-Elliott, Jinyun Yuan, Lindsey M. Kuehm, Gregory D. Felock, Sean A. Crowe and Ryan M. Teague
    Cancer Immunol Res December 1 2016 4 (12) 1016-1026; DOI:10.1158/2326-6066.CIR-16-0159

    Immunotherapy for cancer can be obstructed by immune tolerance, in which antitumor T cells are rendered dysfunctional in the tumor microenvironment. It is shown here that IL2:antibody complexes can reverse established T cell tolerance and restore antitumor immunity.

  • Research Articles
    PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors
    Marcela A. Haro, Chad A. Littrell, Zhaojun Yin, Xuefei Huang and Karen M. Haas
    Cancer Immunol Res December 1 2016 4 (12) 1027-1037; DOI:10.1158/2326-6066.CIR-16-0184

    PD-1 regulates T-cell antitumor responses. PD-1 has now also been found to inhibit B-cell antitumor immunity that is based upon the recognition of tumor-specific glycans, revealing an alternative mechanism by which PD-1 blockade may elicit antitumor responses.

  • Research Articles
    Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
    Mark M. Awad, Robert E. Jones, Hongye Liu, Patrick H. Lizotte, Elena V. Ivanova, Meghana Kulkarni, Grit S. Herter-Sprie, Xiaoyun Liao, Abigail A. Santos, Mark A. Bittinger, Lauren Keogh, Shohei Koyama, Christina Almonte, Jessie M. English, Julianne Barlow, William G. Richards, David A. Barbie, Adam J. Bass, Scott J. Rodig, F. Stephen Hodi, Kai W. Wucherpfennig, Pasi A. Jänne, Lynette M. Sholl, Peter S. Hammerman, Kwok-Kin Wong and Raphael Bueno
    Cancer Immunol Res December 1 2016 4 (12) 1038-1048; DOI:10.1158/2326-6066.CIR-16-0171

    In malignant pleural mesothelioma, immunohistochemical expression of PD-L1 does not accurately predict whether patients respond to treatment with PD-1 pathway inhibitors. Comprehensive immunoprofiling by flow cytometry uncovered immunophenotypes that improve our understanding of response and resistance to checkpoint blockade.

  • Research Articles
    Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
    Yoshihiro Ohue, Koji Kurose, Ryohei Nozawa, Midori Isobe, Yumi Nishio, Tomonori Tanaka, Yoshinori Doki, Takashi Hori, Junya Fukuoka, Mikio Oka and Eiichi Nakayama
    Cancer Immunol Res December 1 2016 4 (12) 1049-1060; DOI:10.1158/2326-6066.CIR-15-0266

    The survival of lung adenocarcinoma patients could be predicted with the use of a discriminant function using as parameters tumor cell expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a), and CD4 and CD8 T-cell infiltration.

  • Research Articles
    Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
    Ellen Moore, Paul E. Clavijo, Ruth Davis, Harrison Cash, Carter Van Waes, Young Kim and Clint Allen
    Cancer Immunol Res December 1 2016 4 (12) 1061-1071; DOI:10.1158/2326-6066.CIR-16-0104

    Many patients with head and neck squamous cell carcinomas do not respond to current immunotherapies. Antitumor responses, with protective memory and control of distant tumors, developed in mouse models after treatment with PD-L1 mAb and synthetic cyclic dinucleotides.

  • Research Articles | AuthorChoice
    Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
    Kipp Weiskopf, Katie L. Anderson, Daisuke Ito, Peter J. Schnorr, Hirotaka Tomiyasu, Aaron M. Ring, Kristin Bloink, Jem Efe, Sarah Rue, David Lowery, Amira Barkal, Susan Prohaska, Kelly M. McKenna, Ingrid Cornax, Timothy D. O'Brien, M. Gerard O'Sullivan, Irving L. Weissman and Jaime F. Modiano
    Cancer Immunol Res December 1 2016 4 (12) 1072-1087; DOI:10.1158/2326-6066.CIR-16-0105

    Targeting CD47 and CD20 to stimulate macrophage phagocytosis was effective in preclinical xenograft models of canine lymphoma in mice. This immunotherapeutic strategy has the potential to benefit companion animals and to inform future targeting studies in humans.

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers
    Acknowledgment to Reviewers
    Cancer Immunol Res December 1 2016 4 (12) 1088-1089; DOI:10.1158/2326-6066.CIR-4-12-Reviewers

Back to top
PreviousNext
Cancer Immunology Research: 4 (12)
December 2016
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Meeting Report
  • Cancer Immunology at the Crossroads
  • Research Articles
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement